Engineered Vascular Plug Shrinks By 40 Percent Inside Patients

Medical researchers have tracked how a specialized hydrogel material shrinks and densifies inside human blood vessels after stopping dangerous internal bleeding. The observational study reveals that the engineered substance gradually breaks down its soft components over the course of a year while leaving behind a durable metal framework that keeps blood vessels permanently blocked.

Internal bleeding and hypervascular tumors, which are growths filled with an excessive network of blood vessels, demand rapid intervention by interventional radiologists. Doctors typically perform transarterial embolization, a minimally invasive procedure where they thread tiny catheters through blood vessels to deliver plugging agents that cut off blood flow to a bleeding site or tumor. Traditional tools include metal coils, liquid glues, and particles, but each carries specific limitations such as shifting out of place or failing to resorb correctly.

The material evaluated in this investigation is known as the Obsidio Conformable Embolic, a ready-to-use hydrogel composed of bioresorbable gelatin, synthetic silicate nanoplatelets, water, and tantalum, which is a heavy metal powder that shows up clearly on medical scans. When injected into a targeted vessel, the shear-thinning substance conforms tightly to vascular walls and immediately halts blood flow. Until now, doctors lacked detailed human data describing how this complex mixture evolves inside the body over extended periods.

To uncover what happens after delivery, investigators analyzed data from 21 patients who underwent embolization procedures for acute bleeding or hypervascular tumors between October 2023 and April 2026. The clinical evaluation, published in CVIR Endovascular, followed individuals who had at least two computed tomography scans after their operations, allowing researchers to track changes in volume and radiodensity over time.

How the Embolic Cast Shrinks and Hardens Inside the Body

The research team measured the size of the embolic material across multiple follow-up intervals ranging from 12 days to nearly a year post-procedure. At the first follow-up, which occurred at a median of 12 days, the mean volume of the embolic cast dropped to about 89 percent of its original size. By the second follow-up at a median of 36 days, the volume decreased further to roughly 79.5 percent of the baseline measurement.

Longer-term scans showed continued volumetric reduction, with the cast decreasing to about 60 percent of its initial volume by the fifth follow-up at a median of 356 days. At the same time, the density of the material measured in Hounsfield units exhibited an initial upward trend during the early weeks, reflecting the progressive loss of lower-density gelatin and water, which left behind a more concentrated aggregation of high-density tantalum.

Despite this significant shrinkage, follow-up imaging confirmed that none of the treated vessels reopened. The occlusion remained structurally sound without any evidence of distal embolization or cast fragmentation.

Comparing Biomimetic Remodeling to Traditional Embolization Agents

The observed physical transformation represents a process known as biomimetic remodeling, where the body’s natural healing response interacts directly with an implanted device. Preclinical models indicate that local immune cells such as macrophages and giant cells gradually break down the gelatin matrix and silicate components over a span of 90 days. This leaves behind the tantalum particles embedded within a permanently fibrosed vessel lumen by 180 days.

This dynamic differs substantially from older technologies. Metal coils provide mechanical blockage but can compact over time and lead to vessel reopening. Liquid glues form static, non-resorbable structures that do not change significantly on imaging, while traditional gelatin sponges degrade so rapidly that vessels often recanalize within days or weeks. The engineered hydrogel balances these extremes by shrinking at a decelerating rate while maintaining permanent vascular closure.

Study Limitations and What Lies Ahead

The authors noted several important limitations in their work, including its retrospective, single-center design and a relatively small cohort of 21 patients comprising 30 treated vessels. Because scans were ordered based on routine clinical necessity rather than a strict research schedule, the timing of follow-up imaging varied considerably among patients. Furthermore, the study combined different clinical indications, such as high-flow traumatic hemorrhages and vascular aneurysms, which introduced physiological diversity into the data.

Larger prospective studies with standardized imaging timelines are necessary to confirm these findings and determine whether this unique material behavior translates into reduced re-bleeding rates or other long-term clinical benefits for patients. For now, the work establishes a baseline radiographic profile that helps physicians distinguish normal material resorption from potential complications.

The research was published in CVIR endovascular on October 24, 2026.